Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LCAT | P04180 | 1/20 | 0.45 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.39 |
| ▸ | HPGDS | O60760 | 1/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.38 |
| ▸ | SYK | P43405 | 2/20 | 0.38 |
| ▸ | NOTUM | Q6P988 | 3/20 | 0.38 |
| ▸ | DEGS1 | O15121 | 1/20 | 0.38 |
| ▸ | OGA | O60502 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | CCNC | P24863 | 1/20 | 0.37 |
| ▸ | CDK8 | P49336 | 1/20 | 0.37 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.37 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16648684 | 0.82 | MAPT (0.56) | MEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL16769753 | 0.81 | LCAT (0.42) | LCATHRH3SYKNOTUMDEGS1 | |
| SCHEMBL18664802 | 0.78 | HRH3 (0.43) | LCATHRH3HPGDSMEN1MAPT | |
| SCHEMBL16769739 | 0.78 | CHRNB2 (0.54) | LCATOGAMAPT | |
| SCHEMBL784764 | 0.77 | LCAT (0.41) | LCATHPGDS | |
| SCHEMBL16769746 | 0.75 | ACACB (0.56) | LCATHRH3 | |
| SCHEMBL27902608 | 0.74 | LCAT (0.38) | LCATHRH3MAPT | |
| SCHEMBL16769749 | 0.74 | ACACB (0.57) | LCATHRH3 | |
| SCHEMBL16769744 | 0.74 | LCAT (0.47) | LCATHRH3 | |
| SCHEMBL16769752 | 0.74 | SLC6A9 (0.41) | LCATHRH3NOTUMDEGS1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9150575-B2 | Piperidinylpyrazolopyridine derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2015-10-06 | — | — | US | disclosed |
| US-20150152102-A1 | PIPERIDINYLPYRAZOLOPYRIDINE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2015-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150152102-A1 | PIPERIDINYLPYRAZOLOPYRIDINE DERIVATIVE | LCAT, LPL, LCLAT1 | LCAT 1/4885HRH3 3681/4885HPGDS 661/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.